Literature DB >> 16003133

Non-alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum.

Ana Cristina Guidorizzi de Siqueira1, Helma P Cotrim, Raquel Rocha, Fernando M Carvalho, Luiz A R de Freitas, Danyella Barreto, Leandro Gouveia, Luciana Landeiro.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has been associated with several metabolic conditions (MC) and secondary causes, but the relationship between insulin resistance (IR) and the underlying aetiology of NAFLD has not been extensively explored.
OBJECTIVE: To determine the frequency of IR among NAFLD patients and to describe IR according to risk factors and histological findings of the disease.
METHODOLOGY: A case-series study of 64 patients with clinical and histological diagnosis of NAFLD. IR was calculated by homeostasis model assessment (HOMA) and IR was considered when HOMA > or = 3. Histological grades of NAFLD were: stage 1, steatosis isolated; stage 2, steatosis and inflammation; stage 3, steatosis and ballooning degeneration; stage 4, steatosis and fibrosis and/or Mallory bodies. Fibrosis was graded 0-4 (cirrhosis).
RESULTS: IR was found in 21 (33%) patients. Among those with IR, 16 patients (76%) had associated MC and five patients (24%) had exposure to petrochemicals. The mean value of HOMA varied from 3.5 in NAFLD associated with MC to 1.6 in patients with exposure to petrochemicals (P < 0.03). Waist circumference was the metabolic factor most strongly associated with IR (P < 0.005). Steatohepatitis (NASH) was observed in 54 (84.3%) cases. The HOMA mean value was significantly higher in patients with advanced fibrosis.
CONCLUSIONS: IR occurred in 33% of the NAFLD patients, being more frequent among those with MC than among those with exposure to petrochemicals. The presence of IR in cases with advanced fibrosis suggests that it may influence the prognosis of NAFLD.

Entities:  

Mesh:

Year:  2005        PMID: 16003133     DOI: 10.1097/00042737-200508000-00010

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  9 in total

1.  Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  Hüseyin Saadettin Uslusoy; Selim Giray Nak; Macit Gülten
Journal:  World J Hepatol       Date:  2011-08-27

Review 2.  Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index.

Authors:  Qing Pang; Jing-Yao Zhang; Si-Dong Song; Kai Qu; Xin-Sen Xu; Su-Shun Liu; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

3.  Decrease in fasting insulin secretory function correlates with significant liver fibrosis in Japanese non-alcoholic fatty liver disease patients.

Authors:  Norimasa Araki; Hirokazu Takahashi; Ayako Takamori; Yoichiro Kitajima; Hideyuki Hyogo; Yoshio Sumida; Saiyu Tanaka; Keizo Anzai; Shinichi Aishima; Kazuaki Chayama; Kazuma Fujimoto; Yuichiro Eguchi
Journal:  JGH Open       Date:  2020-06-09

4.  Synergistic effect of fatty liver and smoking on metabolic syndrome.

Authors:  Po-Hsin Chiang; Tsui-Yen Chang; Jong-Dar Chen
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

5.  Liver histology according to the presence of metabolic syndrome in nonalcoholic fatty liver disease cases.

Authors:  Hüseyin Saadettin Uslusoy; Selim-Giray Nak; Macit Gülten; Zeynep Biyikli
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

6.  Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound.

Authors:  Alessandro de Moura Almeida; Helma Pinchemel Cotrim; Daniel Batista Valente Barbosa; Luciana Gordilho Matteoni de Athayde; Adimeia Souza Santos; Almir Galvão Vieira Bitencourt; Luiz Antonio Rodrigues de Freitas; Adriano Rios; Erivaldo Alves
Journal:  World J Gastroenterol       Date:  2008-03-07       Impact factor: 5.742

Review 7.  Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease.

Authors:  I N Guha; J Parkes; P R Roderick; S Harris; W M Rosenberg
Journal:  Gut       Date:  2006-11       Impact factor: 23.059

8.  Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients.

Authors:  Alexandre Losekann; Antonio C Weston; Angelo A de Mattos; Cristiane V Tovo; Luis A de Carli; Marilia B Espindola; Sergio R Pioner; Gabriela P Coral
Journal:  Int J Mol Sci       Date:  2015-10-23       Impact factor: 5.923

9.  Erchen Decoction and Linguizhugan Decoction Ameliorate Hepatic Insulin Resistance by Inhibiting IRS-1Ser307 Phosphorylation In Vivo and In Vitro.

Authors:  Huicun Zhang; Na Ta; Pengmin Chen; Hongbing Wang
Journal:  Evid Based Complement Alternat Med       Date:  2017-05-29       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.